CATHERINE MUROMBEDZI
HEALTH CORRESPONDENT
Zimbabwe is among 10 countries selected globally to roll out the twice a year injectable HIV prevention. The good news was announced through a statement by the partners, USAID, Global Fund and Gilead Sciences. The rollout of Lenacapavir (LEN) in Zimbabwe will focus on protecting pregnant and breastfeeding women, a vulnerable population at higher risk of HIV transmission.
The Deputy Minister of Health and Child Care, Hon Sleiman Kwidini said the country is set to roll out the injectable PrEP HIV prevention LEN as a pilot study in January 2026.
A pilot study is done after successful clinical trials.
Lenacapavir clinical trials, specifically the PURPOSE 2 trials, were held across 88 sites in Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the United States.
Another trial, PURPOSE 1, for adolescent girls and young women, took place in South Africa and Uganda.
The manufacturer, Gilead Sciences announced in Germany in July 2024, at the International AIDS Conference.
Speaking in a telephone interview, Hon Kwidini said Zimbabwe was pleased.
“As a country, we are honoured to be among the 10 countries selected globally. We expect the doses anytime. Supported by USAID through the Global Fund, we were allocated a quarter of a million United States dollars. The injectable will be purchased right from the manufacture, Gilead. As the Ministry of Health we will train nurses, raise awareness by crafting correct messages. Lenacapavir is an HIV prevention injectable, so anyone who feels to be at risk is eligible. The modalities will be worked out but everyone sexually active and feels at risk of getting HIV infection is welcome,” said Hon Kwidini.

With Zimbabwe having recorded around 13 000 new HIV infections in 2023, (NAC), Lenacapavir will help in closing the tap on new infections.
“As a country, our cold chain and storage meets Lenacapavir storage requirements. Facilities kept COVID-19 vaccines in 2021 and beyond and this gave experience to even small facilities on vaccines and medicines, so storage will not be an issue. Staff will be trained to lookout for severe reactions, and this too, was set up during the COVID-19 era,” said Hon Kwidini.
“We have attained the 95-95-95 targets. We are upping our prevention as we aim to ending AIDS by 2030,” said the Deputy Minister.
“This is more than medicine — it advances us on a pathway to a safer, stronger, and healthier future,” Dr Madzima said of lenacapavir.
Dr Bernard Madzima, the CEO of the National AIDS Council of Zimbabwe, said this development marks a significant step towards ending new HIV infections in the country.
He welcomed the rollout, expected when mapping and modalities by the Ministry were through.
“The introduction of Lenacapavir, a twice yearly anti HIV prevention injectable marks a significant step towards ending new HIV infections.
It offers a promising solution for individuals at risk of contracting the HIV virus. In a large-scale clinical trial, more than 99% of people who received LEN remained HIV-negative. This breakthrough treatment has the potential to save millions of lives worldwide.
“By prioritising these groups, Zimbabwe aims to safeguard the health of the next generation and reduce the risk of mother-to-child transmission of HIV. The introduction of lenacapavir is part of a broader effort to strengthen Zimbabwe’s healthcare systems. Through partnerships with organisations like Gilead Sciences and the Global Fund, the country is working to empower its healthcare infrastructure and ensure that Lenacapavir is accessible and affordable for those who need it,” said Dr Madzima.
“This is more than medicine — it advances us on a pathway to a safer, stronger, and healthier future,” Dr Madzima added.

A young woman living openly with HIV, Phyllis Mavushe said the prevention injection is indeed empowering.
“Some women and girls had difficult in taking pre-exposure prophylaxis pills as they feared being questioned by a partner who would raise the card asking: ‘So you don’t trust me?’ Some partners would become abusive upon finding out that their wife is taking prevention pills.
The twice a year injection is a breakthrough. But still, this prevents HIV not other STIs, so young people, young women, should be empowered to negotiate for safer sex and protect themselves. My other concern though, is sustainability — it will create demand, as it’s the most discreet way of HIV prevention. If no child is to be born HIV positive, then prevention through user friendly ways like LEN must be accessible. The choice in the prevention basket improves. However, amidst severe funding cuts, where 40% plus of funding is gone, expansion of the injectable, in my view, will be constrained. My concern is: Will it be sustainable?” asked Phyllis who holds a Masters in Clinical Psychology from the Midlands State University.

Gilead Sciences announced lenacapavir’s 100% efficacy in preventing HIV infections in cisgender women at the 25th International AIDS Conference in Germany in 20024.
This twice-yearly injectable outperforms daily oral Truvada, marking a significant advancement in HIV prevention and showcasing Gilead’s commitment to innovative research.
An advocate to an AIDS-free nation, Tapiwanashe Mapindani said prevention is always better than cure.
“Prevention is better than cure. This is really a progressive move, while we are dealing with the funding cuts by USAID and PEPFAR, the same USAID is now funding pre-exposure prophylaxis drug, Lenacapavir. We had many clients exhausted from taking the daily HIV prevention pill. So this comes in handy defeating the defaulting rates. Zimbabwe being a country that has achieved the 95-95-95 targets, this will help us maintain that progress,” said Tapiwanashe Mapindani, a Member of the National AIDS Council’s Technical Working Group on Gender, HIV/AIDS.
By ending AIDS, Zimbabwe will view the one time HIV/AIDS epidemic like any other disease. HIV will not warrant any special treatment.
The introduction of LEN is part of a broader effort to strengthen Zimbabwe’s healthcare systems. Through partnerships with organisations like Gilead Sciences, USAID and the Global Fund, the country is working to empower its healthcare infrastructure and ensure that Lenacapavir is accessible and affordable for those who need it.

Meanwhile, in Geneva, Switzerland, the AIDS Vaccine Advocacy Coalition (AVAC), welcomes parallel announcements from the Gates Foundation and Unitaid on strategic investments to accelerate the development of, access to and price reduction for generic versions of injectable lenacapavir (LEN).
“These investments are a vitally important step in translating the remarkable science of LEN into public health impact,” said Mitchell Warren, Executive Director of AVAC.
“With these agreements, injectable LEN for PrEP gets closer to the price of daily oral PrEP, $40 per person per year, for low and middle-income national governments. This means national programmes in many, but not all, countries can begin planning for 2027, at which time ongoing oral PrEP and LEN use will be available at similar prices, meaning many countries will be truly able to offer people who need prevention choice when it comes to the PrEP method that best meets their needs. This could be a transformational moment in HIV prevention if political will, coordination, and further procurement investment meet this moment to deliver LEN with speed, scale and equity to all communities and populations who need and want prevention options. Many questions remain, but in this current environment, we need to seize opportunities and good news when we can.”
These new commitments to accelerate access to generic versions of LEN come on the heels of the Global Fund and PEPFAR re-committing to their December 2024 announcement of reaching two million people with LEN for PrEP within three years, with drug supplies coming from the originator company, Gilead Sciences. Among the outstanding questions from these new commitments is the price of the required oral loading dose for LEN, which is needed to achieve high efficacy. While the cost of ongoing use of LEN for PrEP would be similar to the cost of a year of daily oral PrEP, anyone initiating or restarting LEN for PrEP needs an oral loading dose of LEN. This oral loading dose is not included in the price mentioned in the Gates and Unitaid deals, and supply chains and purchasers need to include this extra cost in their calculations.
“The ‘two million in three years’ ambition from Global Fund and PEPFAR must be seen as a floor and not a ceiling,” said Warren.
“The global PrEP data that AVAC tracks show a more ambitious goal, getting LEN to at least 1.5 million next year alone, is achievable and necessary.
Ultimately, LEN must reach more than five million people per year to have real impact, build a sustainable market, and drive prices down even further. This means we must act faster and think bigger,” said Warren.
● Feedback: [email protected]



Spanked on pussy free videosTeen wreslingMommy likes dickVeags strip mapBlack interracial sex vidWhat’s your sexual styleBack room gay sexSamantha phillips sex movieSuck own escortFrre interracial sex moviesLinssay lohan nakedFuck bitches get moneyNude trish stratusNude wrestling women in europeZoe held captive pornLani lane hardcoreBahamas adult hotelsUncut russian cockClassy teen nudeUkranian naked girlsDouble end dildo videoGauge porn duckyPorn related searches on googleBinding breast illustrationCheap breast cancer pinsFree6 adult powered by phpbbGrams of protein in chicken breastWich country wins the best boobsVintage wedding bridalFree xxx direct moviesJust the cuntRedhead epic tripodsTeenage facial feminization surgeryFree hardcore spy pornvideos
Here is my blog – https://mobxvideos.com
Expanding HIV prevention options can improve access for many communities. Long-acting preventive treatments may help people who find daily routines challenging. How do you think this rollout will influence HIV prevention efforts locally?
I jusdt likje the vvaluable information youu provie oon our articles.
I wikl bookmar your webhlog annd takke a look
aat gain hsre frequently. I’m reelatively sure I wull bee tolld loots oof neww stff
prolper here! Good luck ffor thhe next! xnxx